Background: Patients with inflammatory bowel disease (IBD) post-liver transplant (LT) may have bowel inflammation requiring biologic therapy. We aimed to evaluate the safety of combination biologic and antirejection therapy in IBD patients after LT from a tertiary center case series and an updated literature review.


Adverse Effects, Biological Products, Cholangitis, Clostridium Infections, Complications, Crohn's Disease, Etiology, IBD, Immunosuppression Therapy, Inflammatory Bowel Disease, Liver Transplant, Liver Transplantation, Sclerosing, therapeutic use, Ulcerative Colitis

Read More